19 citations
,
April 2020 in “Dermatologic Therapy” This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.
January 2018 in “Surgical and Cosmetic Dermatology” This review provides an up-to-date analysis of the efficacy and safety of five-alpha reductase inhibitors, specifically finasteride and dutasteride, for treating benign prostatic hyperplasia and male androgenetic alopecia, highlighting their FDA approval history and current use.
1 citations
,
January 2012 in “Daehan namseong gwahag hoeji” This study found that dutasteride was more effective than finasteride in reducing total prostate volume and PSA levels and improving symptoms in patients with benign prostate hyperplasia.
1 citations
,
November 2010 in “Anticancer Research” This study concluded that both finasteride and dutasteride therapies significantly increased chromogranin A serum levels in men with benign prostatic hyperplasia, suggesting an activation of neuroendocrine differentiation.
20 citations
,
January 2004 in “PubMed” This review discusses the pharmacologic effects, safety, and efficacy of dutasteride and finasteride for BPH, finding similar clinical benefits but greater DHT reduction with dutasteride and reports no new trial results.
47 citations
,
January 2003 in “Current opinion in urology” This review discusses recent advancements in understanding the use of 5 alpha-reductase inhibitors for benign prostatic hyperplasia, indicating that dual isoenzyme inhibitors like dutasteride may enhance treatment outcomes, but no new clinical results are presented.